This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 21, 2017 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
PreScription: Compounding Pharmacy Issues for 2017 |
Vol. 21 No. 1 |
4 |
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3 |
Vol. 21 No. 1 |
6 |
When to Compound Medications for Veterinary Patients |
Vol. 21 No. 1 |
19 |
Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications |
Vol. 21 No. 1 |
22 |
Why You Should Become an International Academy of Compounding Pharmacists Member |
Vol. 21 No. 1 |
28 |
Analytic Methods Used in Quality Control in a Compounding Pharmacy |
Vol. 21 No. 1 |
31 |
Basics of Compounding with Dilutions and Concentrates |
Vol. 21 No. 1 |
39 |
Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms |
Vol. 21 No. 1 |
47 |
Calculations |
Vol. 21 No. 1 |
58 |
Clindamycin 10-mg/mL Oral Suspension |
Vol. 21 No. 1 |
60 |
Diazoxide 10-mg/mL Oral Suspension |
Vol. 21 No. 1 |
61 |
Infliximab 1% Ophthalmic Solution |
Vol. 21 No. 1 |
62 |
Nifedipine 0.5% Rectal Ointment |
Vol. 21 No. 1 |
63 |
Tetracaine Hydrochloride 0.5% Ophthalmic Solution |
Vol. 21 No. 1 |
64 |
Zonisamide 10-mg/mL Oral Suspension |
Vol. 21 No. 1 |
65 |
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate |
Vol. 21 No. 1 |
66 |
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride |
Vol. 21 No. 1 |
76 |
A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding |
Vol. 21 No. 1 |
83 |
PreScription: Whatever Happened to Common Sense? |
Vol. 21 No. 2 |
92 |
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies |
Vol. 21 No. 2 |
95 |
Restructuring the Art of Health by Pharmacists: Formulation Designs with Oral Vehicles--Teaching Pharmacy Students |
Vol. 21 No. 2 |
105 |
Consultation for Human, Veterinary, and Compounded Medications |
Vol. 21 No. 2 |
111 |
The International Academy of Compounding Pharmacists Introduces a New President |
Vol. 21 No. 2 |
116 |
Quality Control: (Material) Safety Data Sheets |
Vol. 21 No. 2 |
118 |
Basics of Compounding: 3D Printing--Pharmacy Applications, Part 1 |
Vol. 21 No. 2 |
127 |
Accuracy Considerations in Sterile Compounding |
Vol. 21 No. 2 |
133 |
Calculations |
Vol. 21 No. 2 |
144 |
Azathioprine 10-mg/mL Oral Suspension |
Vol. 21 No. 2 |
146 |
Candesartan Cilexetil 8 mg Liquid-Filled Capsules |
Vol. 21 No. 2 |
147 |
Furosemide 10-mg/mL Oral Suspension |
Vol. 21 No. 2 |
148 |
Ketoconazole 20-mg/mL Oral Suspension |
Vol. 21 No. 2 |
149 |
Stability of Alprostadil in 0.9% Sodium Chloride Stored in Polyvinyl Chloride Containers |
Vol. 21 No. 2 |
150 |
Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-Use Date |
Vol. 21 No. 2 |
154 |
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions |
Vol. 21 No. 2 |
160 |
Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs |
Vol. 21 No. 2 |
164 |
Suspensions as a Valuable Alternative to Extemporaneously Compounded Capsules |
Vol. 21 No. 2 |
171 |
PreScription: United States Pharmacopeia Chapter <800> Comments and Alternatives |
Vol. 21 No. 3 |
180 |
Adventures in the Environmental World and Environmental Microbiology Sampling of Air for Pharmaceutical Sterile Compounding |
Vol. 21 No. 3 |
182 |
Microbiologic Testing for 503A Sterile-Compounding Pharmacies |
Vol. 21 No. 3 |
193 |
Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report |
Vol. 21 No. 3 |
205 |
International Academy of Compounding Pharmacists Legislative/Regulatory Update |
Vol. 21 No. 3 |
212 |
Basics of Compounding: 3D Printing--Pharmacy Applications, Part 2 |
Vol. 21 No. 3 |
215 |
Basics of Sterile Compounding: Manipulating Peptides and Proteins |
Vol. 21 No. 3 |
223 |
Calculations |
Vol. 21 No. 3 |
230 |
Candesartan Cilexetil 0.1-mg/mL to 2.0-mg/mL Oral Suspension |
Vol. 21 No. 3 |
232 |
Ketoconazole 20-mg/mL in SyrSpend SF pH4 Oral Suspension |
Vol. 21 No. 3 |
233 |
Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base |
Vol. 21 No. 3 |
234 |
Meloxicam 1% Topical Gel |
Vol. 21 No. 3 |
235 |
Ofloxacin 0.3% Ophthalmic Solution |
Vol. 21 No. 3 |
236 |
PVP Iodine 10% Antiseptic Cream |
Vol. 21 No. 3 |
237 |
Tri-Est, Progesterone, and Testosterone in Versatile, Phytobase, Fitaline, and HRT Supreme Cream Bases |
Vol. 21 No. 3 |
238 |
Trimethoprim 10-mg/mL Oral Suspension |
Vol. 21 No. 3 |
239 |
Updated Stability Data for Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Minoxidil in Espumil |
Vol. 21 No. 3 |
240 |
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats |
Vol. 21 No. 3 |
242 |
Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance |
Vol. 21 No. 3 |
247 |
Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes |
Vol. 21 No. 3 |
251 |
Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions |
Vol. 21 No. 3 |
255 |
PreScription: Just Think About It! |
Vol. 21 No. 4 |
268 |
Change Is In the Air: What You Need to Know About Pharmacy Ventilation Under United States Pharmacopeia <800> |
Vol. 21 No. 4 |
271 |
Component Selection for Sterile Compounding |
Vol. 21 No. 4 |
277 |
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas |
Vol. 21 No. 4 |
282 |
The International Academy of Compounding Pharmacists Applauds the Leadership of Congressmen Griffith and Cuellar in Introducing Bill HR 2871 |
Vol. 21 No. 4 |
290 |
Basics of Compounding: 3D Printing: Pharmacy Applications, Part 3: Compounding, Formulation Considerations, and the Future |
Vol. 21 No. 4 |
293 |
Basics of Sterile Compounding: Excipients Used in Injections |
Vol. 21 No. 4 |
301 |
Calculations |
Vol. 21 No. 4 |
310 |
Betamethasone 0.1% and Neomycin 0.6% Gel-Cream |
Vol. 21 No. 4 |
312 |
Castor Oil 50% in Modified Pluronic Lecithin Organogel Gel |
Vol. 21 No. 4 |
313 |
Copper Sulfate, Magnesium Sulfate, Phenylephrine, and Guaifenesin Pluronic Lecithin Organogel |
Vol. 21 No. 4 |
314 |
Disopyramide 100-mg Capsules |
Vol. 21 No. 4 |
315 |
Ferrous Sulfate 30-mg Fe/mL Oral Drops |
Vol. 21 No. 4 |
316 |
Reteplase Injection |
Vol. 21 No. 4 |
317 |
Sertraline Hydrochloride 10-mg/mL Oral Suspension |
Vol. 21 No. 4 |
318 |
Tacrolimus 0.06% Ophthalmic Drops |
Vol. 21 No. 4 |
319 |
Torsemide 10-mg/mL Injection |
Vol. 21 No. 4 |
320 |
Tranilast 8% Pluronic Lecithin Organogel Gel |
Vol. 21 No. 4 |
321 |
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) |
Vol. 21 No. 4 |
322 |
Compounded Levofloxacin Triple Therapy is Safe and Effective for Refractory Helicobacter pylori |
Vol. 21 No. 4 |
330 |
Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt |
Vol. 21 No. 4 |
334 |
Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 |
Vol. 21 No. 4 |
339 |
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia |
Vol. 21 No. 4 |
347 |
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs |
Vol. 21 No. 5 |
356 |
Compounding Opportunities in Urology |
Vol. 21 No. 5 |
358 |
Child-safety Containers/Devices and Compounding |
Vol. 21 No. 5 |
364 |
Documentation: Records and Reports |
Vol. 21 No. 5 |
373 |
IACP Legislative/Regulatory Update |
Vol. 21 No. 5 |
382 |
Quality Control: Bar Codes and Bar Code Scanners for Unit-Dose Medications in a Healthcare Setting |
Vol. 21 No. 5 |
384 |
Basics of Compounding: 3D Printing--Pharmacy Applications: Geometric Shape Effects on 3D Printing |
Vol. 21 No. 5 |
388 |
Basics of Sterile Compounding: Particulate Matter |
Vol. 21 No. 5 |
395 |
Calculations |
Vol. 21 No. 5 |
406 |
Acetylcysteine Solutions for Inhalation |
Vol. 21 No. 5 |
408 |
Carbamazepine 25-mg/mL in SyrSPend SF pH4 Oral Suspension |
Vol. 21 No. 5 |
409 |
Etoposide 20-mg/mL Injection |
Vol. 21 No. 5 |
410 |
Fentanyl Citrate 50-mcg/mL Injection |
Vol. 21 No. 5 |
411 |
Fluoxymesterone 10-mg Capsules |
Vol. 21 No. 5 |
412 |
Ioversol Injection |
Vol. 21 No. 5 |
413 |
Levocarnitine 100-mg/mL Oral Solution |
Vol. 21 No. 5 |
414 |
Peritoneal Dialysis Solution with 1.5%, 2.5%, or 4.25% Dextrose |
Vol. 21 No. 5 |
415 |
Tacrolimus 0.3-mg/mL Ophthalmic Solution |
Vol. 21 No. 5 |
416 |
Vancomycin 50 mg/mL in Oral Syrup Suspension |
Vol. 21 No. 5 |
417 |
Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3) |
Vol. 21 No. 5 |
418 |
Stability of Dalteparin 1,000 Unit/mL in 0.9% Sodium Chloride for Injection in Polypropylene Syringes |
Vol. 21 No. 5 |
426 |
Physicochemical Stability of an Oral Suspension of Trimethoprim 20 mg/mL in Combination with Sulfadiazine 200 mg/mL in PCCA Base SuspendIt |
Vol. 21 No. 5 |
430 |
Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags |
Vol. 21 No. 5 |
436 |
PreScription: Issues with the NAMS 2017 Hormone Therapy Position Statement |
Vol. 21 No. 6 |
444 |
Feline Transdermal Formulation Considerations |
Vol. 21 No. 6 |
446 |
Orodispersible Films for Compounding Pharmacies |
Vol. 21 No. 6 |
454 |
Features of Pharmaceutical Compounding in the Republic of Tajikistan |
Vol. 21 No. 6 |
463 |
Join the Partnership for Personalized Prescriptions (P3) Advocacy Effort! |
Vol. 21 No. 6 |
468 |
Basics of Compounding: Hot Melt Extrusion |
Vol. 21 No. 6 |
471 |
Basics of Compounding: Compounding Irrigation Solutions for Sterile and Nonsterile Preparations |
Vol. 21 No. 6 |
481 |
Calculations |
Vol. 21 No. 6 |
488 |
Amitriptyline 20 mg/mL in OraPlus:OraSweet Suspension |
Vol. 21 No. 6 |
490 |
Dapsone 2 mg/mL in SyrSpend SF pH4 Oral Suspension |
Vol. 21 No. 6 |
491 |
Fluconazole 10% in RECURA Cream |
Vol. 21 No. 6 |
492 |
Haloperidol 5-mg/mL Injection |
Vol. 21 No. 6 |
493 |
Hydroxychloroquine Sulfate 25 mg/mL in Oral Mix or Oral Mix SF |
Vol. 21 No. 6 |
494 |
Promethazine Hydrochloride 12.5 mg/0.1 mL in PLO Gel |
Vol. 21 No. 6 |
495 |
Spironolactone 5 mg/mL in SuspendIt Oral Suspension |
Vol. 21 No. 6 |
496 |
Tolmetin 400-mg Capsules |
Vol. 21 No. 6 |
497 |
Trace Elements Injection 5 |
Vol. 21 No. 6 |
498 |
Vancomycin 5-mg/mL Injection |
Vol. 21 No. 6 |
499 |
To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid |
Vol. 21 No. 6 |
500 |
Validation of the Technological Process of the Preparation "Milk by Vidal" |
Vol. 21 No. 6 |
513 |
Auditing Safety of Compounding and Reconstituting of Intravenous Medicines on Hospital Wards in Finland |
Vol. 21 No. 6 |
518 |
Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives |
Vol. 21 No. 6 |
530 |